FDA creates Office of New Drug Quality

Share this article:
The FDA yesterday announced the establishment of its Office of New Drug Quality Assessment (ONDQA), a newly created division of the Office of New Drug Chemistry (ONDC) within the FDA's Office of Pharmaceutical Science.
"ONDQA is being created to facilitate the implementation of a modern, risk-based pharmaceutical quality assessment system to replace the current chemistry, manufacturing and controls (CMC) review system in ONDC," the FDA said in a statement. "ONDQA will be responsible for evaluating CMC section of an IND, NDA, and NDA supplement for drugs regulated by CDER."
The new office will become effective November 1, 2005 and will be headed by Moheb Nasr, currently serving as director, ONDC.
"ONDQA is a science-based organization designed to be more efficient, effective, and flexible in managing CMC issues and workload," said FDA spokeswoman Christine Parker.  "While any new organizational structure is subject to fine-tuning, I believe that the establishment of ONDQA is an important step in the continuing improvement of FDA's CMC review practices for the 21st Century."
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...